

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Insulin Lispro (Admelog pen)

Initiation (new start) criteria: Non-formulary **insulin lispro (Admelog pen)** will be covered on the prescription drug benefit when the following criteria are met:

- The member has a documented allergic reaction to an inactive ingredient in Humalog AND unbranded biologic insulin lispro that is not present in Admelog

-AND-

Meets 1 of the following clinical criteria:

- Diagnosis of Type 1 diabetes mellitus -OR-
- On insulin pump therapy -OR-
- Use while pregnant -OR-
- Diagnosis of Type 2 diabetes mellitus and insulinopenia* -OR-
- Patients with Type 2 diabetes mellitus who require intensive glycemic control (4 or more insulin injections per day) AND have recurrent hypoglycemia with regular insulin defined as 3 or more episodes of low blood sugar (less than 70 mg/dL) over the preceding 30 days that persists despite regular insulin dose adjustments

-AND-

Meets 1 of the following Insulin Pen Criteria:

- Unable to draw up insulin accurately from a vial with a syringe due to young age, visual impairment, physical disabilities (i.e., amputations, tremors/Parkinson's disease, rheumatoid arthritis), or history of IV drug use -OR-
- Pediatric patient who is required to use such devices by school -OR-
- Type 1 diabetes mellitus

* Insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Insulin Lispro (Admelog pen)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **insulin lispro (Admelog pen)** will be covered on the prescription drug benefit when the following criteria are met:

- The member has a documented allergic reaction to an inactive ingredient in Humalog AND unbranded biologic insulin lispro that is not present in Admelog

-AND-

Meets 1 of the following clinical criteria:

- Diagnosis of Type 1 diabetes mellitus -OR-
- On insulin pump therapy -OR-
- Use while pregnant -OR-
- Diagnosis of Type 2 diabetes mellitus and insulinopenia* -OR-
- Patients with Type 2 diabetes mellitus who require intensive glycemic control (4 or more insulin injections per day) AND have recurrent hypoglycemia with regular insulin defined as 3 or more episodes of low blood sugar (less than 70 mg/dL) over the preceding 30 days that persists despite regular insulin dose adjustments

-AND-

Meets 1 of the following Insulin Pen Criteria:

- Unable to draw up insulin accurately from a vial with a syringe due to young age, visual impairment, physical disabilities (i.e., amputations, tremors/Parkinson's disease, rheumatoid arthritis), or history of IV drug use -OR-
- Pediatric patient who is required to use such devices by school -OR-
- Type 1 diabetes mellitus

* Insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.